• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

环孢素抑制剂阿利匹韦(Debio 025)抑制 SARS-CoV-2 感染。

Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025).

机构信息

Research Team "Viruses, Hepatology, Cancer," Institut Mondor de Recherche Biomédicale, INSERM U955, Créteil, France.

Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France.

出版信息

Antimicrob Agents Chemother. 2020 Jun 23;64(7). doi: 10.1128/AAC.00876-20.

DOI:10.1128/AAC.00876-20
PMID:32376613
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7318051/
Abstract

Cyclophilins play a key role in the life cycle of coronaviruses. Alisporivir (Debio 025) is a nonimmunosuppressive analogue of cyclosporine with potent cyclophilin inhibition properties. Alisporivir reduced SARS-CoV-2 RNA production in a dose-dependent manner in Vero E6 cells, with a 50% effective concentration (EC) of 0.46 ± 0.04 μM. Alisporivir inhibited a postentry step of the SARS-CoV-2 life cycle. These results justify rapidly conducting a proof-of-concept phase 2 trial with alisporivir in patients with SARS-CoV-2 infection.

摘要

亲环素在冠状病毒的生命周期中发挥着关键作用。阿利司匹韦(Debio 025)是一种非免疫抑制性环孢素类似物,具有很强的亲环素抑制特性。阿利司匹韦以剂量依赖的方式降低了 Vero E6 细胞中的 SARS-CoV-2 RNA 产生,其 50%有效浓度(EC)为 0.46±0.04 μM。阿利司匹韦抑制了 SARS-CoV-2 生命周期的进入后步骤。这些结果证明,在 SARS-CoV-2 感染患者中快速进行阿利司匹韦的概念验证阶段 2 试验是合理的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fb7/7318051/814618a2ff70/AAC.00876-20-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fb7/7318051/814618a2ff70/AAC.00876-20-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fb7/7318051/814618a2ff70/AAC.00876-20-f0001.jpg

相似文献

1
Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025).环孢素抑制剂阿利匹韦(Debio 025)抑制 SARS-CoV-2 感染。
Antimicrob Agents Chemother. 2020 Jun 23;64(7). doi: 10.1128/AAC.00876-20.
2
Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome-Coronavirus 2 In Vitro When Administered After Virus Infection.干扰素-β-1a 对病毒感染后给药时体外严重急性呼吸综合征冠状病毒 2 的抑制作用。
J Infect Dis. 2020 Aug 4;222(5):722-725. doi: 10.1093/infdis/jiaa350.
3
Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering with Early Steps of the Replication Cycle.苏拉明通过干扰复制周期的早期步骤抑制细胞培养中的 SARS-CoV-2 感染。
Antimicrob Agents Chemother. 2020 Jul 22;64(8). doi: 10.1128/AAC.00900-20.
4
COVID-19 Pandemic: Time to Revive the Cyclophilin Inhibitor Alisporivir.新冠疫情:是时候重启亲环素抑制剂阿利匹韦了。
Clin Infect Dis. 2020 Nov 19;71(16):2191-2194. doi: 10.1093/cid/ciaa587.
5
In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect.体外试验表明,羟氯喹与阿奇霉素联合使用对 SARS-CoV-2 具有协同作用。
Microb Pathog. 2020 Aug;145:104228. doi: 10.1016/j.micpath.2020.104228. Epub 2020 Apr 25.
6
Lithium for the 2019 novel coronavirus.锂用于治疗2019新型冠状病毒。 (不过从专业角度看,该表述不太符合医学常理,可能存在信息偏差,仅按要求翻译)
Med Hypotheses. 2020 Sep;142:109822. doi: 10.1016/j.mehy.2020.109822. Epub 2020 May 7.
7
SARS-CoV-2 and the safety margins of cell-based biological medicinal products.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)与基于细胞的生物药品的安全边际
Biologicals. 2020 Nov;68:122-124. doi: 10.1016/j.biologicals.2020.08.010. Epub 2020 Aug 29.
8
[Role of cyclophilin A during coronavirus replication and the antiviral activities of its inhibitors].[亲环素A在冠状病毒复制过程中的作用及其抑制剂的抗病毒活性]
Sheng Wu Gong Cheng Xue Bao. 2020 Apr 25;36(4):605-611. doi: 10.13345/j.cjb.200049.
9
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.美国食品药品监督管理局批准的药物伊维菌素可抑制 SARS-CoV-2 的体外复制。
Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.
10
Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production.阿利泼司他抑制肝细胞亲环素可降低 HBV 复制和乙型肝炎表面抗原产生。
Gastroenterology. 2015 Feb;148(2):403-14.e7. doi: 10.1053/j.gastro.2014.10.004. Epub 2014 Oct 8.

引用本文的文献

1
Broad-Spectrum Antiviral Activity of Cyclophilin Inhibitors Against Coronaviruses: A Systematic Review.亲环素抑制剂对冠状病毒的广谱抗病毒活性:一项系统综述
Int J Mol Sci. 2025 Aug 15;26(16):7900. doi: 10.3390/ijms26167900.
2
Evaluating the potential of non-immunosuppressive cyclosporin analogs for targeting Toxoplasma gondii cyclophilin: Insights from structural studies.评估非免疫抑制性环孢菌素类似物靶向弓形虫亲环素的潜力:结构研究的见解。
Protein Sci. 2024 Oct;33(10):e5157. doi: 10.1002/pro.5157.
3
Cyclophilin inhibition as a strategy for the treatment of human disease.

本文引用的文献

1
Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication.环孢素 A 和非免疫抑制剂衍生物在人冠状病毒 229E 复制过程中对细胞亲环素和病毒核衣壳蛋白的影响。
Antiviral Res. 2020 Jan;173:104620. doi: 10.1016/j.antiviral.2019.104620. Epub 2019 Oct 18.
2
Cyclophilins and cyclophilin inhibitors in nidovirus replication.冠状病毒复制中的亲环素和亲环素抑制剂。
Virology. 2018 Sep;522:46-55. doi: 10.1016/j.virol.2018.06.011. Epub 2018 Jul 12.
3
Feline coronavirus replication is affected by both cyclophilin A and cyclophilin B.
抑制亲环蛋白作为治疗人类疾病的一种策略。
Front Pharmacol. 2024 Jul 8;15:1417945. doi: 10.3389/fphar.2024.1417945. eCollection 2024.
4
Taming Conformational Heterogeneity on Ion Racetrack to Unveil Principles that Drive Membrane Permeation of Cyclosporines.驯服离子赛道上的构象异质性以揭示驱动环孢素膜渗透的原理。
JACS Au. 2024 Mar 16;4(4):1458-1470. doi: 10.1021/jacsau.4c00011. eCollection 2024 Apr 22.
5
Drug Repurposing: Insights into Current Advances and Future Applications.药物再利用:当前进展与未来应用洞察
Curr Med Chem. 2025;32(3):468-510. doi: 10.2174/0109298673266470231023110841.
6
Staying Ahead of the Game: How SARS-CoV-2 has Accelerated the Application of Machine Learning in Pandemic Management.走在游戏前面:SARS-CoV-2 如何加速机器学习在大流行管理中的应用。
BioDrugs. 2023 Sep;37(5):649-674. doi: 10.1007/s40259-023-00611-8. Epub 2023 Jul 18.
7
Conserved Conformational Dynamics Reveal a Key Dynamic Residue in the Gatekeeper Loop of Human Cyclophilins.保守构象动力学揭示了人类亲环素中环肽门控环中的关键动态残基。
J Phys Chem B. 2023 Apr 13;127(14):3139-3150. doi: 10.1021/acs.jpcb.2c08650. Epub 2023 Mar 29.
8
Molecular insight into the specific interactions of the SARS-Coronavirus-2 nucleocapsid with RNA and host protein.对 SARS-CoV-2 核衣壳与 RNA 和宿主蛋白特异性相互作用的分子洞察。
Protein Sci. 2023 Apr;32(4):e4603. doi: 10.1002/pro.4603.
9
Markers of blood-brain barrier disruption increase early and persistently in COVID-19 patients with neurological manifestations.标志物的血脑屏障破坏增加早,持续在 COVID-19 患者有神经症状。
Front Immunol. 2022 Dec 15;13:1070379. doi: 10.3389/fimmu.2022.1070379. eCollection 2022.
10
Development of a robust and convenient dual-reporter high-throughput screening assay for SARS-CoV-2 antiviral drug discovery.开发一种稳健、便捷的双报告基因高通量筛选检测方法,用于发现抗 SARS-CoV-2 的药物。
Antiviral Res. 2023 Feb;210:105506. doi: 10.1016/j.antiviral.2022.105506. Epub 2022 Dec 21.
猫冠状病毒的复制受亲环蛋白A和亲环蛋白B两者的影响。
J Gen Virol. 2017 Feb;98(2):190-200. doi: 10.1099/jgv.0.000663. Epub 2017 Mar 13.
4
Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model.阿利匹韦能在细胞培养中抑制中东呼吸综合征冠状病毒和严重急性呼吸综合征冠状病毒的复制,但在小鼠模型中对严重急性呼吸综合征冠状病毒感染没有抑制作用。
Virus Res. 2017 Jan 15;228:7-13. doi: 10.1016/j.virusres.2016.11.011. Epub 2016 Nov 10.
5
Genetic deficiency and polymorphisms of cyclophilin A reveal its essential role for Human Coronavirus 229E replication.亲环素A的基因缺陷和多态性揭示了其对人冠状病毒229E复制的重要作用。
Curr Opin Virol. 2015 Oct;14:56-61. doi: 10.1016/j.coviro.2015.08.004. Epub 2015 Aug 27.
6
Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection.阿利司泼韦联合利巴韦林,无干扰素或联合聚乙二醇干扰素,用于治疗丙型肝炎病毒 2 或 3 型感染。
Hepatology. 2015 Oct;62(4):1013-23. doi: 10.1002/hep.27960. Epub 2015 Aug 10.
7
Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir.人冠状病毒 NL63 的复制依赖于亲环素 A,并受非免疫抑制性环孢菌素 A 衍生物(包括阿利司匹韦)的抑制。
Virus Res. 2014 May 12;184:44-53. doi: 10.1016/j.virusres.2014.02.010. Epub 2014 Feb 22.
8
Suppression of feline coronavirus replication in vitro by cyclosporin A.环孢素 A 抑制猫冠状病毒在体外的复制。
Vet Res. 2012 Apr 30;43(1):41. doi: 10.1186/1297-9716-43-41.
9
The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors.严重急性呼吸综合征冠状病毒-宿主相互作用组:亲环素作为泛冠状病毒抑制剂的靶标鉴定。
PLoS Pathog. 2011 Oct;7(10):e1002331. doi: 10.1371/journal.ppat.1002331. Epub 2011 Oct 27.
10
Cyclosporin A inhibits the replication of diverse coronaviruses.环孢素 A 抑制多种冠状病毒的复制。
J Gen Virol. 2011 Nov;92(Pt 11):2542-2548. doi: 10.1099/vir.0.034983-0. Epub 2011 Jul 13.